Drug news
TC 5214 fails first Phase III trial for Major Depressive Disorder
Phase III results of TC 5214, a nicotinic channel blocker from AstraZeneca/Targacept, were disappointing in the first study (RENAISSANCE 3) of four studies as an adjunct therapy to an antidepressant in patients with major depressive disorder who do not respond adequately to initial treatment. The study did not meet its primary endpoint of change on the commonly-used Montgomery-Asberg Depression Rating Scale after eight weeks of treatment with TC-5214 as compared to placebo. However a New Drug Application in the USA s planned for the second half of 2012. A European filing is not expected before 2015.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins